MOTS-c & Mitochondrial Peptides
Mitochondrial-derived peptides — exciting biology, immature clinic.
A solo narrator walks you through the key takeaways of "MOTS-c & Mitochondrial Peptides". First generation takes ~10–20 s, then it's cached for everyone.
What's covered
Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.
By the end of this module you will be able to
- L01Place MOTS-c on the evidence map; explain why current clinic offerings are speculative.
What you should walk away believing
Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.
What this means for you
MOTS-c is a small peptide encoded by mitochondrial DNA. Animal studies suggest it may improve insulin sensitivity. Human clinical evidence essentially doesn't exist yet.
Counsel patients that 'mitochondrial peptide therapy' offerings are pre-evidence — the receptor target is not even fully defined.
What the data say
Test yourself
Lock it in — review what's due
Sources cited in this module
- [1]The mitochondrial-derived peptide humanin and agingKim SJ. et al. · Aging Cell · 2018Review · T3
- [2]The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasisLee C. et al. · Cell Metabolism · 2015Mechanism / preclinical · T3